-
公开(公告)号：EP3875475A1
公开(公告)日：2021-09-08
申请号：EP19898340.5
申请日：2019-12-20
申请人： Jiangsu Hengrui Medicine Co., Ltd. , Shanghai Hengrui Pharmaceutical Co., Ltd. , Shanghai Shengdi Pharmaceutical Co., Ltd
发明人： CHEN, Lei , HU, Qiyue , GE, Hu , LIN, Yuan , WANG, Hongwei , OU, Yangchao , KONG, Xianglin , LIAO, Cheng , ZHANG, Lianshan
IPC分类号： C07K14/55 , C07K17/08 , C07K19/00 , C12N15/26 , C12N15/63 , C12P21/02 , A61K38/20 , A61K47/60 , A61K47/62 , A61K47/68 , A61P35/00 , A61P37/00
摘要： Provided is a human interleukin-2 (IL-2) variant having one or more amino acid mutations or a derivative thereof. The IL-2 variant or derivative thereof has increased stability compared to wild-type IL-2 and improved properties as an immunotherapeutic agent. Also disclosed are an immunoconjugate and a pharmaceutical composition which comprise the human IL-2 variant or derivative thereof, a polynucleotide molecule encoding same, a vector, a host cell and a preparation method therefor, as well as the pharmaceutical uses of the IL-2 variant or derivative thereof and the immunoconjugate or pharmaceutical composition comprising the L-2 variant or derivative thereof.
-
公开(公告)号：EP3495384A1
公开(公告)日：2019-06-12
申请号：EP17836368.5
申请日：2017-08-01
发明人： LIU, Deyu , WANG, Hongwei , ZHAO, Liang , WANG, Feifei , ZENG, Xiang , WANG, Tao , WANG, Yali , DAI, Yulu
摘要： Provided is an acylated derivative of human insulin or an analogue thereof. Specifically disclosed is an acylated derivative of a human insulin analogue, or zinc complex thereof; said acylated derivative is longer-lasting than existing insulin analogues and acylated derivatives thereof, its blood glucose reduction is more steady, and it is more stable in storage.
-
公开(公告)号：EP3805257A1
公开(公告)日：2021-04-14
申请号：EP19808332.1
申请日：2019-05-23
发明人： ZHAO, Liangliang , HAN, Guangjie , NIU, Ningning , LI, Na , LIU, Yanwei , WANG, Hongwei
摘要： Disclosed is a method for preparing a precursor of a recombinant human insulin or an analogue thereof, comprising: a. bacterial fermentation, centrifuging a fermentation broth in a continuous flow to collect a supernatant; b. filtering the supernatant in step (a) by means of a hollow fiber membrane and collecting the filtrate; and c. purifying the filtrate in the step (b) by means of a chromatography column. The method has the advantages of streamlined steps, scalability, no use of organic solvents, high yield, etc. The purity of the insulin precursor can exceed 90%, the host cell protein removal rate exceeds 90%, and the exogenous DNA removal rate is 89% or greater, achieving less than 0.1 ng/mg.
-
-
搜索结果
3 条记录 (耗时 0.009 秒)
